Efficient and biologically relevant consensus strategy for Parkinson’s disease gene prioritization

[1]  J. Kordower,et al.  PGC−1α Promoter Methylation in Parkinson’s Disease , 2015, PloS one.

[2]  F. Cavalcanti,et al.  Splicing: is there an alternative contribution to Parkinson’s disease? , 2015, neurogenetics.

[3]  Reinhard Schneider,et al.  Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease , 2015, Neurobiology of Disease.

[4]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[5]  Prudence Mutowo-Meullenet,et al.  The GOA database: Gene Ontology annotation updates for 2015 , 2014, Nucleic Acids Res..

[6]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[7]  W. Ko,et al.  RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease , 2014, Neurobiology of Disease.

[8]  Alison I. Bernstein,et al.  The vesicular monoamine transporter 2: An underexplored pharmacological target , 2014, Neurochemistry International.

[9]  Kong-Joo Lee,et al.  N-Terminal Truncated UCH-L1 Prevents Parkinson's Disease Associated Damage , 2014, PloS one.

[10]  Zhicheng Lin,et al.  SLC6A3 is a risk factor for Parkinson's disease: A meta-analysis of sixteen years’ studies , 2014, Neuroscience Letters.

[11]  Shiwei Duan,et al.  Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta-analysis. , 2014, Biomedical reports.

[12]  Luigi Bubacco,et al.  Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease? , 2014, Ageing Research Reviews.

[13]  G. Tseng,et al.  Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders , 2014, Genes, brain, and behavior.

[14]  L. Friberg,et al.  Prepulse inhibition is associated with attention, processing speed, and 123I-FP-CIT SPECT in Parkinson's disease. , 2014, Journal of Parkinson's disease.

[15]  Lynn A. Hyde,et al.  MitoPark mice, an animal model of Parkinson’s disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A2A antagonist SCH 412348 , 2014, Psychopharmacology.

[16]  D. German,et al.  The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism , 2013, Experimental Neurology.

[17]  Eduardo Tejera,et al.  Co-expression network analysis and genetic algorithms for gene prioritization in preeclampsia , 2013, BMC Medical Genomics.

[18]  V. Kutala,et al.  Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects. , 2013, Indian Journal of Biochemistry & Biophysics.

[19]  M. Chesselet,et al.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease , 2013, Progress in Neurobiology.

[20]  Yan Zhang,et al.  Research and applications: An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer , 2013, J. Am. Medical Informatics Assoc..

[21]  S. Goldwurm,et al.  Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease , 2013, Neurobiology of Aging.

[22]  Alison I. Bernstein,et al.  Vesicular Integrity in Parkinson’s Disease , 2013, Current Neurology and Neuroscience Reports.

[23]  Danail Bonchev,et al.  A Network View on Parkinson's Disease , 2013, Computational and structural biotechnology journal.

[24]  Or Zuk,et al.  Identification of transcriptional regulators in the mouse immune system , 2013, Nature Immunology.

[25]  H. Deng,et al.  Genetic analysis of NR4A2 gene in a large population of Han Chinese patients with Parkinson's disease , 2013, European journal of neurology.

[26]  David N Hauser,et al.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism , 2013, Neurobiology of Disease.

[27]  J. Rilstone,et al.  Brain dopamine-serotonin vesicular transport disease and its treatment. , 2013, The New England journal of medicine.

[28]  T. Cunha-Oliveira,et al.  Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. , 2012, Free radical biology & medicine.

[29]  Sung-Rae Cho,et al.  Gene Expression Profiling in Parkinson’s Disease , 2013 .

[30]  H. Pall,et al.  The Role of Dopamine Replacement on the Behavioural Phenotype of Parkinson’s Disease , 2013, Behavioural neurology.

[31]  Hongyu Diao,et al.  Gene Expression Profiling Combined with Bioinformatics Analysis Identify Biomarkers for Parkinson Disease , 2012, PloS one.

[32]  P. Cisek.  Making decisions through a distributed consensus , 2012, Current Opinion in Neurobiology.

[33]  Bin Zhang,et al.  Identification of key pathways and transcription factors related to Parkinson disease in genome wide , 2012, Molecular Biology Reports.

[34]  Mario Albrecht,et al.  Recent approaches to the prioritization of candidate disease genes , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[35]  D. Lovinger,et al.  Conditional Expression of Parkinson's Disease-Related Mutant α-Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1 , 2012, The Journal of Neuroscience.

[36]  Y. Bozzi,et al.  The atypical homeoprotein Pbx1a participates in the axonal pathfinding of mesencephalic dopaminergic neurons , 2012, Neural Development.

[37]  H. Fernandez,et al.  Nonmotor complications of Parkinson disease , 2012, Cleveland Clinic Journal of Medicine.

[38]  H. Deng,et al.  Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson’s disease , 2012, European journal of neurology.

[39]  R. Lucchini,et al.  Olfactory functions at the intersection between environmental exposure to manganese and Parkinsonism. , 2012, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[40]  N. Greig,et al.  A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. , 2012, CNS & neurological disorders drug targets.

[41]  Yanjun Zeng,et al.  Overview of tyrosine hydroxylase in Parkinson's disease. , 2012, CNS & neurological disorders drug targets.

[42]  P. Riederer,et al.  Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study , 2012, Parkinson's disease.

[43]  Xing-Ming Zhao,et al.  Identifying disease genes and module biomarkers by differential interactions , 2012, J. Am. Medical Informatics Assoc..

[44]  D. Goldstein,et al.  Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease , 2012, PloS one.

[45]  Vladimir N Uversky,et al.  Α-synuclein misfolding and Parkinson's disease. , 2012, Biochimica et biophysica acta.

[46]  Talia N. Lerner,et al.  RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits , 2012, Neuron.

[47]  T. Cunha-Oliveira,et al.  Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse. , 2012, Free radical biology & medicine.

[48]  Faramarz Valafar,et al.  Empirical comparison of cross-platform normalization methods for gene expression data , 2011, BMC Bioinformatics.

[49]  A. Southwick,et al.  Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium , 2011, Journal of the Neurological Sciences.

[50]  Daniel R. Salomon,et al.  Strategies for aggregating gene expression data: The collapseRows R function , 2011, BMC Bioinformatics.

[51]  H. Fukuyama,et al.  Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population , 2011, BMC neurology.

[52]  J. Doorn,et al.  Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. , 2011, Chemico-biological interactions.

[53]  M. V. van Boxtel,et al.  Brain‐specific fatty acid‐binding protein is elevated in serum of patients with dementia‐related diseases , 2011, European journal of neurology.

[54]  R. Katzenschlager,et al.  Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease , 2011, Neurobiology of Aging.

[55]  J. Saavedra,et al.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications , 2011, Psychoneuroendocrinology.

[56]  W. Tong,et al.  Cross-Platform Comparison of Microarray-Based Multiple-Class Prediction , 2011, PloS one.

[57]  Jee-Young Lee,et al.  Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[58]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[59]  Howard J. Federoff,et al.  Microarrays in Parkinson’s disease: A systematic approach , 2006, NeuroRX.

[60]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[61]  J. Rosenbaum,et al.  Insm1 promotes the transition of olfactory progenitors from apical and proliferative to basal, terminally dividing and neuronogenic , 2011, Neural Development.

[62]  Heather J. Ruskin,et al.  Cross-Platform Microarray Data Normalisation for Regulatory Network Inference , 2010, PloS one.

[63]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[64]  M. Pirovano,et al.  Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson’s disease , 2010, Journal of Neural Transmission.

[65]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[66]  Bruce J. Aronow,et al.  ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems , 2010, Nucleic Acids Res..

[67]  H. Fung,et al.  SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[68]  C. Rowe,et al.  In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 , 2010, Journal of Nuclear Medicine.

[69]  H. Braak,et al.  A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.

[70]  K. Fiedler,et al.  Olfactory Impairment Predicts Brain Atrophy in Parkinson's Disease , 2009, The Journal of Neuroscience.

[71]  H. Reichmann,et al.  Olfactory dysfunction as a diagnostic marker for Parkinson’s disease , 2009, Expert review of neurotherapeutics.

[72]  B. Jeon,et al.  Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[73]  M. Smidt,et al.  Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons , 2009, Development.

[74]  N. Lehman.  The ubiquitin proteasome system in neuropathology , 2009, Acta Neuropathologica.

[75]  M. Cookson,et al.  Characterisation of a novel NR4A2 mutation in Parkinson's disease brain , 2009, Neuroscience Letters.

[76]  J. Doorn,et al.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. , 2009, Chemical research in toxicology.

[77]  C. Warren Olanow,et al.  The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.

[78]  James L. Melville,et al.  Better than Random? The Chemotype Enrichment Problem , 2009, J. Chem. Inf. Model..

[79]  A. Rodriguez-Perez,et al.  The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease , 2009, Journal of neurochemistry.

[80]  N. Hattori,et al.  Programmed cell death‐2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease , 2009, FEBS letters.

[81]  Marie-Pier Champagne,et al.  The Polycomb Group Gene Bmi1 Regulates Antioxidant Defenses in Neurons by Repressing p53 Pro-Oxidant Activity , 2009, The Journal of Neuroscience.

[82]  C. Kruse,et al.  Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death , 2009, Brain pathology.

[83]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[84]  Tao Li,et al.  [Association of the polymorphisms in NURR1 gene with Parkinson's disease]. , 2008, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[85]  J. Jankovic,et al.  Decreased NURR1 gene expression in patients with Parkinson's disease , 2008, Journal of the Neurological Sciences.

[86]  D. Dickson,et al.  Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.

[87]  A. Prochiantz,et al.  Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: a new genetic model for Parkinson's disease? , 2008, Parkinsonism & related disorders.

[88]  D. Gerrelli,et al.  Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis , 2008, The Journal of comparative neurology.

[89]  Jack Y. Yang,et al.  A comparative study of different machine learning methods on microarray gene expression data , 2008, BMC Genomics.

[90]  M. Singh,et al.  Polymorphism in environment responsive genes and association with Parkinson disease , 2008, Molecular and Cellular Biochemistry.

[91]  M. Wieler,et al.  Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease , 2008, Annals of neurology.

[92]  Bin Zhang,et al.  Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R , 2008, Bioinform..

[93]  Simona Distinto,et al.  Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? , 2008, J. Comput. Aided Mol. Des..

[94]  C. Tanaka,et al.  Inositol 1,4,5-trisphosphate binding sites in the brain: Regional distribution, characterization, and alterations in brains of patients with Parkinson's disease , 2008, Journal of Molecular Neuroscience.

[95]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[96]  K. Lim,et al.  Role of the ubiquitin proteasome system in Parkinson's disease , 2007, BMC Biochemistry.

[97]  K. Hashimoto,et al.  Fabp7 Maps to a Quantitative Trait Locus for a Schizophrenia Endophenotype , 2007, PLoS biology.

[98]  Sean R. Davis,et al.  GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..

[99]  Yih-Ru Wu,et al.  Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese parkinson's disease , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[100]  D. Maraganore,et al.  A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.

[101]  V. Vasiliou,et al.  Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase , 2007, Pharmacological Reviews.

[102]  M. Frosch,et al.  Effects of gender on nigral gene expression and parkinson disease , 2007, Neurobiology of Disease.

[103]  D. Bilecen,et al.  Functional imaging of the cerebral olfactory system in patients with Parkinson’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[104]  J. Labandeira-Garcia,et al.  Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons , 2007, Neurobiology of Aging.

[105]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[106]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[107]  J. Haavik,et al.  Tyrosine hydroxylase and Parkinson's disease , 1998, Molecular Neurobiology.

[108]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[109]  N. Quinn,et al.  NR4A2 genetic variation in sporadic Parkinson's disease: A genewide approach , 2006, Movement disorders : official journal of the Movement Disorder Society.

[110]  Sonja W. Scholz,et al.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.

[111]  Ling Lin,et al.  Axonal Growth Regulation of Fetal and Embryonic Stem Cell‐Derived Dopaminergic Neurons by Netrin‐1 and Slits , 2006, Stem cells.

[112]  Marten P. Smidt,et al.  Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice , 2006, Proceedings of the National Academy of Sciences.

[113]  N. Bohnen,et al.  Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[114]  J. Labandeira-Garcia,et al.  Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism , 2006, Neuropharmacology.

[115]  L. Racacho,et al.  Translated mutation in the Nurr1 gene as a cause for Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[116]  Charles J. Wilson,et al.  RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion , 2006, Nature Neuroscience.

[117]  J. Jankovic,et al.  Nurr1 in Parkinson's disease and related disorders , 2006, The Journal of comparative neurology.

[118]  D. Mash,et al.  Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. , 2006, Gene expression.

[119]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[120]  L. Moran,et al.  Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.

[121]  Eibe Frank,et al.  Speeding Up Logistic Model Tree Induction , 2005, PKDD.

[122]  J. Labandeira-Garcia,et al.  Angiotensin‐converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6‐hydroxydopamine rat model of Parkinsonism , 2005, Journal of neuroscience research.

[123]  Atul J. Butte,et al.  Systematic survey reveals general applicability of "guilt-by-association" within gene coexpression networks , 2005, BMC Bioinformatics.

[124]  S. Horvath,et al.  A General Framework for Weighted Gene Co-Expression Network Analysis , 2005, Statistical applications in genetics and molecular biology.

[125]  F. Middleton,et al.  Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[126]  S. Mandel,et al.  Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin‐Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC‐70 , 2005, Annals of the New York Academy of Sciences.

[127]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[128]  Raymond J. Mooney,et al.  Creating diversity in ensembles using artificial data , 2005, Inf. Fusion.

[129]  Y. Itoyama,et al.  Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice , 2005, European Neuropsychopharmacology.

[130]  グリュンブラット、エドナ,et al.  Diagnostic test for Parkinson's disease , 2005 .

[131]  Eibe Frank,et al.  Logistic Model Trees , 2003, Machine Learning.

[132]  Fuhui Long,et al.  Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy , 2003, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[133]  Rotterdam.  Incidence of parkinsonism and Parkinson disease in a general population: The Rot terdam Study , 2005 .

[134]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[135]  Yi Zhao,et al.  Nurr1 mutational screen in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[136]  A. Hofman,et al.  Incidence of parkinsonism and Parkinson disease in a general population , 2004, Neurology.

[137]  S. Mandel,et al.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.

[138]  Graeme Eisenhofer,et al.  Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine , 2004, Pharmacological Reviews.

[139]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[140]  A. Destée,et al.  Assessment of Nurr1 nucleotide variations in familial Parkinson’s disease , 2004, Neuroscience Letters.

[141]  M. Farrer,et al.  A limited role for DJ1 in Parkinson disease susceptibility , 2004, Neurology.

[142]  Y. Agid,et al.  Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease , 2004, Neurology.

[143]  T. Foroud,et al.  Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[144]  Parvesh Bubber,et al.  Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3‐nitropropionic acid neurotoxicity , 2004, Journal of neurochemistry.

[145]  N. Campbell.  Genetic association database , 2004, Nature Reviews Genetics.

[146]  João Gama,et al.  Functional Trees , 2001, Machine Learning.

[147]  Yong Wang,et al.  Using Model Trees for Classification , 1998, Machine Learning.

[148]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[149]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[150]  David S. Park,et al.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Yi Zhao,et al.  Genetic analysis of Nurr1 haplotypes in Parkinson's disease , 2003, Neuroscience Letters.

[152]  Raymond J. Mooney,et al.  Constructing Diverse Classifier Ensembles using Artificial Training Examples , 2003, IJCAI.

[153]  A. Kingsbury,et al.  Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson’s disease , 2003, Neurochemistry International.

[154]  G. Sedvall,et al.  NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[155]  M. Beal.  Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[156]  D. Simon,et al.  A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. , 2003, Archives of neurology.

[157]  Yi Zhao,et al.  Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[158]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[159]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[160]  J. Jankovic,et al.  Erratum: Mutations in NR4A2 associated with familial Parkinson disease (Nature Genetics (2003) 33 (85-89)) , 2003 .

[161]  Hong Jiang,et al.  Mutations in NR4A2 associated with familial Parkinson disease , 2003, Nature Genetics.

[162]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[163]  W. Longstreth,et al.  Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease. , 2002, Neurotoxicology.

[164]  Geoff Holmes,et al.  Multiclass Alternating Decision Trees , 2002, ECML.

[165]  J. Jankovic,et al.  Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson’s disease , 2002, Neurology.

[166]  A. Barabasi,et al.  Lethality and centrality in protein networks , 2001, Nature.

[167]  W. Weiner,et al.  Comorbidity of the nonmotor symptoms of Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[168]  J. Idle,et al.  Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[169]  H. Checkoway,et al.  Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism , 2000, Journal of neurology, neurosurgery, and psychiatry.

[170]  B. Snel,et al.  STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. , 2000, Nucleic acids research.

[171]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[172]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[173]  J. Friedman.  Special Invited Paper-Additive logistic regression: A statistical view of boosting , 2000 .

[174]  J. Blass,et al.  The α-ketoglutarate dehydrogenase complex in neurodegeneration , 2000, Neurochemistry International.

[175]  A. Quattrone,et al.  The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[176]  J. Blass,et al.  The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. , 2000, Neurochemistry international.

[177]  J. Gorell,et al.  Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.

[178]  E. Tolosa,et al.  Dopamine receptor D2 intronic polymorphism in patients with Parkinson's disease , 1999, Neuroscience Letters.

[179]  E. Altschuler,et al.  Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. , 1999, Medical hypotheses.

[180]  Yoav Freund,et al.  The Alternating Decision Tree Learning Algorithm , 1999, ICML.

[181]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[182]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[183]  Ian H. Witten,et al.  Generating Accurate Rule Sets Without Global Optimization , 1998, ICML.

[184]  Duncan J. Watts,et al.  Collective dynamics of ‘small-world’ networks , 1998, Nature.

[185]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[186]  M A Geyer,et al.  Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. , 1998, Schizophrenia bulletin.

[187]  T. Magnuson,et al.  Targeted disruption of the murine dihydrolipoamide dehydrogenase gene (Dld) results in perigastrulation lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[188]  C D Marsden,et al.  Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease , 1997, Neurology.

[189]  Gregory G. Brown,et al.  Occupational exposures to metals as risk factors for Parkinson's disease , 1997, Neurology.

[190]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[191]  Yoav Freund,et al.  Experiments with a New Boosting Algorithm , 1996, ICML.

[192]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[193]  R. Takayanagi,et al.  cDNA cloning of a NGFI-B/nur77-related transcription factor from an apoptotic human T cell line. , 1995, Journal of immunology.

[194]  S. Greenfield,et al.  Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. , 1995, Free radical biology & medicine.

[195]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[196]  C. C. Johnson,et al.  Parkinson's disease mortality and the industrial use of heavy metals in Michigan , 1993, Movement disorders : official journal of the Movement Disorder Society.

[197]  Christian Grillon,et al.  Gating and habituation of the startle reflex in schizophrenic patients. , 1992 .

[198]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.

[199]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[200]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[201]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[202]  M. Roy,et al.  Facteurs environnementaux dans l'étiologie de la maladie de Parkinson , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[203]  S. Ohta,et al.  Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.

[204]  G. Campanella,et al.  [Parkinson disease and environmental factors]. , 1990, Revue d'épidémiologie et de santé publique.

[205]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[206]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[207]  C. Tanner,et al.  Environmental Factors in the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[208]  A. Carlsson,et al.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.

[209]  C. Marsden,et al.  The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. , 1986, Journal of neural transmission. Supplementum.

[210]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[211]  G. Derringer,et al.  Simultaneous Optimization of Several Response Variables , 1980 .

[212]  Maddocks Ac.  Letter: Sterilisation of cardiac bioptome. , 1974 .

[213]  W. Martin.  Tyrosine hydroxylase deficiency. A unifying concept of Parkinsonism. , 1971, Lancet.

[214]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.